{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:58:54Z","timestamp":1791309534342,"version":"4.3.1"},"reference-count":42,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NIH National Cancer Institute","doi-asserted-by":"crossref","award":["P30CA016672-38"],"award-info":[{"award-number":["P30CA016672-38"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Department of Urology at the University of Texas MD Anderson Cancer Center"},{"name":"MD Anderson Institutional Research Grant"},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","award":["RA230419"],"award-info":[{"award-number":["RA230419"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Translational Molecular Pathology Immunoprofiling Laboratory"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: In a series of 33 patients with advanced penile squamous cell carcinoma (PSCC), we evaluated tissue factor (TF), TROP2, and nectin-4 protein expression as potential therapeutic targets. Expression levels of these proteins were also correlated to clinicopathological characteristics, including high-risk human papillomavirus (HPV), CDKN2A (p16) status, and aberrant p53 expression. Methods: A tissue microarray (TMA) was constructed with three cores per patient tumor (99 total cores). Anti-TF antibody staining was performed by immunohistochemistry, and H-scores for membrane and cytoplasm staining were assessed (range 0\u2013300). The percentage of cores and patient tumors staining positive for TF (\u226510% of tumor cells with at least 1+ intensity in cytoplasm and\/or membrane) and H-scores were described and compared with HPV and p16 status. The association of TF expression with tumor grade, presence of metastatic disease, lymphovascular invasion (LVI), perineural invasion (PNI), aberrant p53 expression, recurrence-free survival (RFS), and cancer-specific survival (CSS) was assessed. Nectin-4 and TROP2 staining and their association with clinical\/pathological data were determined in a similar manner. Results: TF staining was evident in 26 (81.3%) of the cohort and was more prominent in HPV-negative tumors in both the membrane (H-score 69.6 vs. 18.8; p = 0.003) and cytoplasm (H-score 59.2 vs. 17.7, p = 0.007). Cytoplasmic (H-score 61.7 vs. 11.7, p &lt; 0.001) and membrane TF staining (H-score 71.7 vs. 15.0, p &lt; 0.001) favored p16-negative tumors. The p53 status was more likely to be aberrant in the higher TF staining samples (cytoplasm H-score 61.7 vs. 18.3, p = 0.012; membrane H-score 67.5 vs. 20.3, p = 0.006). We observed an association with TROP2 staining and positive p16 status (membrane H-score 120.3 vs. 85, p = 0.052; cytoplasmic H-score 135 vs. 107.5, p = 0.041). We observed an association of TROP2 staining with positive LVI (membrane H-score 136.7 vs. 66.7, p = 0.014; cytoplasmic H-score 110 vs. 93.3, p = 0.04). We found no association between TF, TROP2, or nectin-4 staining with CSS or RFS; however, we suspect that this was due to our small sample size. Conclusions: Our results indicate that TF was expressed in the majority of advanced PSCC with enhanced expression among HPV-independent, p53-aberrant tumors and may represent a novel therapy target in advanced PSCC.<\/jats:p>","DOI":"10.3390\/cancers17213410","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T01:35:11Z","timestamp":1761269711000},"page":"3410","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tissue Factor Expression in Penile Squamous Cell Carcinoma: A Potential Marker of HPV-Independent Disease"],"prefix":"10.3390","volume":"17","author":[{"given":"Jamaal C.","family":"Jackson","sequence":"first","affiliation":[{"name":"Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Johns","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-8543","authenticated-orcid":false,"given":"Leticia","family":"Campos Clemente","sequence":"additional","affiliation":[{"name":"Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Manuel","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaja","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1253-630X","authenticated-orcid":false,"given":"Luisa M.","family":"Solis Soto","sequence":"additional","affiliation":[{"name":"Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad","family":"Chahoud","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-4491","authenticated-orcid":false,"given":"Matthew T.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1697-1840","authenticated-orcid":false,"given":"Curtis A.","family":"Pettaway","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9364-6016","authenticated-orcid":false,"given":"Niki M.","family":"Zacharias","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.urology.2010.03.003","article-title":"Epidemiology and natural history of penile cancer","volume":"76","author":"Ferreira","year":"2010","journal-title":"Urology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(04)01427-5","article-title":"Penile carcinoma: A challenge for the developing world","volume":"5","author":"Misra","year":"2004","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1007\/s00259-023-06586-6","article-title":"New EAU\/ASCO guideline recommendations on sentinel node biopsy for penile cancer and remaining challenges from a nuclear medicine perspective","volume":"51","author":"Vreeburg","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ijrobp.2023.03.066","article-title":"A Prospective Study of Chemoradiotherapy as Primary Treatment in Patients With Locoregionally Advanced Penile Carcinoma","volume":"117","author":"Ottenhof","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.eururo.2023.02.027","article-title":"European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update","volume":"83","author":"Brouwer","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/jnci\/djae034","article-title":"Neoadjuvant platinum-based chemotherapy and lymphadenectomy for penile cancer: An international, multi-institutional, real-world study","volume":"116","author":"Rose","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11864-025-01319-3","article-title":"Emerging Advances in the Molecular Landscape of Penile Cancer and Their Implications for Precision Medicine","volume":"26","author":"Elst","year":"2025","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Rouvinov, K., Mazor, G., Kozlener, E., Meirovitz, A., Shrem, N.S., Abu Saleh, O., Shalata, S., Yakobson, A., and Shalata, W. (2023). Cemiplimab as First Line Therapy in Advanced Penile Squamous Cell Carcinoma: A Real-World Experience. J. Pers. Med., 13.","DOI":"10.3390\/jpm13111623"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.urology.2014.12.049","article-title":"Treatment for Metastatic Penile Cancer After First-line Chemotherapy Failure: Analysis of Response and Survival Outcomes","volume":"85","author":"Wang","year":"2015","journal-title":"Urology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.humpath.2023.10.003","article-title":"Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma","volume":"142","author":"Tekin","year":"2023","journal-title":"Hum. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2022.12.008","article-title":"An Analysis of Nectin-4 (PVRL4) in Penile Squamous Cell Carcinoma","volume":"49","author":"Grass","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1055\/s-0035-1556048","article-title":"Tissue Factor: Old and New Links with Cancer Biology","volume":"41","author":"Versteeg","year":"2015","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1055\/s-0039-1687895","article-title":"Role of Tissue Factor in Tumor Progression and Cancer-Associated Thrombosis","volume":"45","author":"Rondon","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): A multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Chahoud, J., Zacharias, N.M., Pham, R., Qiao, W., Guo, M., Lu, X., Alaniz, A., Segarra, L., Martinez-Ferrer, M., and Gleber-Netto, F.O. (2022). Prognostic Significance of p16 and Its Relationship with Human Papillomavirus Status in Patients with Penile Squamous Cell Carcinoma: Results of 5 Years Follow-Up. Cancers, 14.","DOI":"10.3390\/cancers14246024"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4103\/0256-4947.51806","article-title":"Tissue Microarray: A rapidly evolving diagnostic and research tool","volume":"29","author":"Jawhar","year":"2009","journal-title":"Ann. Saudi Med."},{"key":"ref_18","first-page":"e1699","article-title":"Systematic study of tissue factor expression in solid tumors","volume":"6","author":"Harris","year":"2023","journal-title":"Cancer Rep."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Jeon, Y., Jo, U., Hong, J., Gong, G., and Lee, H.J. (2022). Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10076-7"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer","volume":"42","author":"Klumper","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes","volume":"29","author":"Lombardo","year":"2021","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1038\/s41379-020-0524-1","article-title":"Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status","volume":"33","author":"Kortekaas","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/PGP.0000000000000725","article-title":"The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting","volume":"40","author":"Kobel","year":"2021","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Trias, I., Saco, A., Marimon, L., Lopez Del Campo, R., Manzotti, C., Ordi, O., Del Pino, M., Perez, F.M., Vega, N., and Alos, S. (2023). P53 in Penile Squamous Cell Carcinoma: A Pattern-Based Immunohistochemical Framework with Molecular Correlation. Cancers, 15.","DOI":"10.3390\/cancers15102719"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/modpathol.2017.26","article-title":"HPV-negative penile squamous cell carcinoma: Disruptive mutations in the TP53 gene are common","volume":"30","author":"Kashofer","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-20-4004","article-title":"Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma","volume":"27","author":"Chahoud","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.euf.2022.04.012","article-title":"Establishment and Characterization of Advanced Penile Cancer Patient-derived Tumor Xenografts: Paving the Way for Personalized Treatments","volume":"8","author":"Elst","year":"2022","journal-title":"Eur. Urol. Focus."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1055\/s-0039-1687894","article-title":"Tissue Factor and Cancer: Regulation, Tumor Growth, and Metastasis","volume":"45","author":"Hisada","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2004-05-2042","article-title":"Oncogenic events regulate tissue factor expression in colorectal cancer cells: Implications for tumor progression and angiogenesis","volume":"105","author":"Yu","year":"2005","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00384-011-1164-1","article-title":"Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis","volume":"26","author":"Rao","year":"2011","journal-title":"Int. J. Color. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1373\/clinchem.2009.123695","article-title":"Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN","volume":"55","author":"Regina","year":"2009","journal-title":"Clin. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/JTO.0b013e31817c1b21","article-title":"Tissue factor expression in non-small cell lung cancer: Relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation","volume":"3","author":"Regina","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"ref_33","first-page":"4075","article-title":"Expression of tissue factor in human cervical carcinoma tissue","volume":"16","author":"Zhao","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1200\/EDBK_320411","article-title":"Expanding Our Impact in Cervical Cancer Treatment: Novel Immunotherapies, Radiation Innovations, and Consideration of Rare Histologies","volume":"41","author":"Randall","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"100753","DOI":"10.1016\/j.modpat.2025.100753","article-title":"Spatial Expression of HER2, NECTIN4, and TROP-2 in Muscle-Invasive Bladder Cancer and Metastases: Implications for Pathological and Clinical Management","volume":"38","author":"Dernbach","year":"2025","journal-title":"Mod. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1200\/JCO.2009.22.6324","article-title":"Role of Tissue Factor in Cancer","volume":"27","author":"Kasthuri","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/sj.bjc.6690073","article-title":"Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis","volume":"79","author":"Sawada","year":"1999","journal-title":"Br. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1054\/bjoc.2000.1272","article-title":"Tissue factor expression in breast cancer tissues: Its correlation with prognosis and plasma concentration","volume":"83","author":"Ueno","year":"2000","journal-title":"Br. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1055\/s-0037-1615384","article-title":"Tissue factor expression and metastatic potential of colorectal cancer","volume":"80","author":"Shigemori","year":"1998","journal-title":"Thromb. Haemost."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<295::AID-CNCR8>3.0.CO;2-U","article-title":"Tissue factor expression in human colorectal carcinoma\u2014Correlation with hepatic metastasis and impact on prognosis","volume":"88","author":"Seto","year":"2000","journal-title":"Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2024.03.038","article-title":"Single-cell Atlas of Penile Cancer Reveals TP53 Mutations as a Driver of an Aggressive Phenotype, Irrespective of Human Papillomavirus Status, and Provides Clues for Treatment Personalization","volume":"86","author":"Elst","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-13-2440","article-title":"An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors","volume":"74","author":"Breij","year":"2014","journal-title":"Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3410\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T04:31:53Z","timestamp":1761366713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":42,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["cancers17213410"],"URL":"https:\/\/doi.org\/10.3390\/cancers17213410","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}